
Stem-cell therapy company saved by public funds
A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy.
A government-sponsored investment fund will acquire Holostem, a biotech that produces the only cure for a rare disease that was on the brink of bankruptcy.